McLachlan J - Search Results

1

Olaparib for the treatment of epithelial ovarian cancer.

McLachlan J, Banerjee S. McLachlan J, et al. Expert Opin Pharmacother. 2016;17(7):995-1003. doi: 10.1517/14656566.2016.1165205. Epub 2016 Apr 4. Expert Opin Pharmacother. 2016. PMID: 26967466 Review.

2

Pazopanib in ovarian cancer.

McLachlan J, Banerjee S. McLachlan J, et al. Expert Rev Anticancer Ther. 2015;15(9):995-1005. doi: 10.1586/14737140.2015.1081383. Epub 2015 Aug 20. Expert Rev Anticancer Ther. 2015. PMID: 26296187 Review.

3

Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).

Seifert H, Georgiou A, Alexander H, McLachlan J, Bodla S, Kaye S, Barton D, Nobbenhuis M, Gore M, Banerjee S. Seifert H, et al. Among authors: mclachlan j. Gynecol Oncol. 2015 Nov;139(2):216-20. doi: 10.1016/j.ygyno.2015.08.015. Epub 2015 Aug 28. Gynecol Oncol. 2015. PMID: 26318078

4

Targeted agents and combinations in ovarian cancer: where are we now?

McLachlan J, Lima JP, Dumas L, Banerjee S. McLachlan J, et al. Expert Rev Anticancer Ther. 2016;16(4):441-54. doi: 10.1586/14737140.2016.1162101. Expert Rev Anticancer Ther. 2016. PMID: 26942837 Review.

5

Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.

McLachlan J, Gore M, Banerjee S. McLachlan J, et al. Pharmacogenomics. 2016 Aug;17(12):1353-63. doi: 10.2217/pgs.16.24. Epub 2016 Jul 29. Pharmacogenomics. 2016. PMID: 27469379 Review.

6

The current status of PARP inhibitors in ovarian cancer.

McLachlan J, George A, Banerjee S. McLachlan J, et al. Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24. Tumori. 2016. PMID: 27716873 Review.

7

The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.

McLachlan J, Boussios S, Okines A, Glaessgen D, Bodlar S, Kalaitzaki R, Taylor A, Lalondrelle S, Gore M, Kaye S, Banerjee S. McLachlan J, et al. Clin Oncol (R Coll Radiol). 2017 Mar;29(3):153-160. doi: 10.1016/j.clon.2016.10.002. Epub 2016 Nov 9. Clin Oncol (R Coll Radiol). 2017. PMID: 27838135

8

Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review.

Boussios S, Attygalle A, Hazell S, Moschetta M, McLachlan J, Okines A, Banerjee S. Boussios S, et al. Among authors: mclachlan j. Anticancer Res. 2015 Dec;35(12):6713-22. Anticancer Res. 2015. PMID: 26637887 Review.

9

Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor.

Boussios S, Moschetta M, McLachlan J, Banerjee S. Boussios S, et al. Among authors: mclachlan j. Case Rep Oncol Med. 2015;2015:574708. doi: 10.1155/2015/574708. Epub 2015 Dec 21. Case Rep Oncol Med. 2015. PMID: 26798532 Free PMC article.

10

The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.

George A, McLachlan J, Tunariu N, Della Pepa C, Migali C, Gore M, Kaye S, Banerjee S. George A, et al. Among authors: mclachlan j. BMC Cancer. 2017 Jun 30;17(1):456. doi: 10.1186/s12885-017-3440-0. BMC Cancer. 2017. PMID: 28666422 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

508 results

Search Page

Filters